

Corporate Presentation

September 2019

Legal Warning

Cautionary note regarding forward-looking statements: This presentation contains forward-looking statements, including, but not limited to, statements regarding plans with respect to commercializing our product and product candidates, our translational research program, the expected timing of release of additional data for our product candidates, plans to initiate additional studies for product candidates and timing and design of these studies, plans regarding ongoing studies for existing programs, our liquidity position as of the most recent fiscal quarter end, expectations regarding the adequacy of clinical data to support marketing applications and approvals of product candidates, our intent to file, and potential timing and success of, marketing applications and other regulatory approvals, expectations regarding timing of receiving potential approval of product candidates, expectations regarding prevalence of patients, future regulatory interactions, and the value to be generated by our pipeline. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, such as the regulatory approval process, the timing of our regulatory filings and other matters that could affect sufficiency of existing cash, cash equivalents and short-term investments to fund operations, the availability or commercial potential of our product and product candidates, and our ability to integrate acquired businesses, which are more fully described in our most recent Form 10-Q or Form 10-K under the caption "Risk Factors" and elsewhere in such reports. Any forward-looking statements made by us reflect our current views with respect to future events or to our future financial performance and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by these forward-looking statements. Accordingly, our actual results may materially differ from our current expectations, estimates, and projections. Given these uncertainties, you should not place undue reliance on these forward-looking statements.

Any forward-looking statements made by us in this presentation speak only as of the date of this presentation and represent our estimates and assumptions only as of the date of this presentation. Except as required by law, we assume no obligation, and we disclaim any intent, to update these statements to reflect actual results.

This presentation concerns commercial products as well as discussion of investigational drugs that are under preclinical and/or clinical investigation and which have not yet been approved for marketing by the U.S. Food and Drug Administration (FDA). They are currently limited by Federal law to investigational use, and no representations are made as to their safety or effectiveness for the purposes for which they are being investigated.

Ultragenyx, Ultragenyx Pharmaceutical, Ultragenyx Gene Therapy, Mepsevii, and our logo are our trademarks. Any other trademarks appearing in these slides are the property of their respective holders.



Ultragenyx: Rare by Design, 9 Years from Founding

Exceptional Rare Disease Company

- Forging new approaches
- 14+ indications
- Multiple modalities

Gene Therapy Platform


- 6+ programs
- Clinical POC in 2
- Strong manufacturing

Global Commercial

- 2 approved therapies
- Third potential therapy filed
- N. America, S. America, Europe and Turkey




The RARE Formula for Effective Pipeline Development






Current Focus on Therapeutic Areas with Rare Genetic Disease

Clinical and Commercial Synergies



Pipeline Driving Next Opportunities Across 4 Modes

Picking the best mode for each indication



Diverse Clinical Pipeline Across Metabolic Indications

Candidate	Description	Pre-Clinical	IND	Phase 1	Phase 2	Phase 3	Approved*	Est'd Patients in Dev. World
CRYSVITA*	Anti-FGF23							~48,000
KYOWA KIRIN	monoclonal antibody	τιο						~2,000 - 4,000
Mepsevii (vestronidase alfa-vijbl] injection	Enzyme replacement	MPS 7						~200
UX007	Substrate replacement	LC-FAOD						~8,000-14,000
DTX301	AAV8-OTC Gene Transfer	отс						~10,000
DTX401	AAV8-G6Pase Gene Transfer	GSDIa						~6,000
	AAV-FVIII Gene Transfer	Hemophilia A						~144,000
						Protein	Biologic Gene The	erapy Small Molecule

14+ Translational Research Programs | Advancing One into the Clinic Every 1-2 Years

Near-term Commercial and Clinical Catalysts

Candidate	Disease	2019	2020
Mepsevii Enzyme Replacement	MPS7	Commercial Updates	
Crysvita Anti-FGF23 monoclonal	XLH	Commercial Updates ✓ 64-week pediatric data	
antibody	TIO	Finalize registrational plan (Q3)	
UX007 Substrate Replacement	LC-FAOD	 ✓ Long-term extension data ✓ NDA submission 	
DTX301 AAV8 gene therapy	OTC Deficiency	Ph 1/2 Cohort 3 data (Q4)	Potential Ph3 Initiation
DTX401 AAV8 gene therapy	GSDIa	✓ Ph 1/2 Cohort 1 data ✓ Ph 1/2 Cohort 2 data	 Ph 1/2 Ext Cohort Data Potential Ph3 Initiation
UX701 Gene Therapy	Wilson		IND Submission
UX053 mRNA	GSDIII	IND Enabling Nonclinical Studies, CMC Process Optimization, and Clinical Protocol Development	IND Submission
UX068 Small Molecule	CTD		IND Submission
7			ultrageny




Commercial Update



Mepsevii (vestronidase alfa-vjbk) injection


Presence in Three Major Rare Disease Markets Less than 18 Months Post-Launch



ultrage

Note: Crysvita in North America is profit shared with Kyowa Kirin International (KKI); in Europe (excluding Turkey), KKI is responsible for commercialization; and in Latin America Ultragenyx is responsible for commercialization.

U.S. Patient Access Model Unique model to support and accelerate growth





Strong Crysvita U.S. Launch

Key U.S. Commercial Launch Metrics

As of June 30, 2019

- ~ 1,300 completed start forms
- ~ 530 unique prescribers
- ~ 960 patients on reimbursed, commercial therapy
- In 2Q19, policies (60% private / 40% gov't), nearly full coverage of lives in the U.S.





Crysvita Clinical Data Supports Launch

Pediatric

Crysvita Superiority Over Conventional Therapy

Substantial Rickets Healing after 64 Weeks on Treatment

- 86.2% on Crysvita
- 18.8% on oral phosphate, vitamin D regimen

<u>Adult</u>

Significant Clinical Improvement with Crysvita Treatment

Substantial Fracture Healing

- Serum phosphorus normal
- Improvements in stiffness, pain, physical functioning





UX007 for Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)

Phase 2 substrate replacement therapy (oral liquid)

UX007 for LC-FAOD NDA submitted July 2019

- LC-FAOD: Inability to convert fat into energy
- Key symptoms/prognosis:
 - Hypoglycemia, muscle rupture, heart failure
 - Mortality ~50%¹; a cause of SIDS (newborn screened in U.S.)
- Standard of care: Diet and MCT² oil
- UX007 Phase 2 data:
 - Clinically meaningful reduction in frequency and duration of major medical events
- U.S. prevalence: ~2,000 3,500

Status:

✓ Submitted NDA to FDA





UX007 NDA Submitted


NDA submission includes:

- Company-sponsored Phase 2 (n=29)
- Long-term extension study (n=75)
- Retrospective medical review (n=20)
- Expanded access (n=70)
- Investigator-sponsored study (n=32)

NDA submitted July 2019



Extension Study Supports Sustained Clinically Meaningful Impact of UX007



* Percent reductions based on total UX007 treatment period (Phase 2 + Ext periods)

** 156 weeks on Tx for Ph2 rollover patients and median of 63 weeks for naïve patients

Safety profile in the long-term extension study (n=75) consistent with what has been previously observed with UX007



AAV Gene Therapy Platform

Gene Therapy Platform Supported by People, Pipeline, and Manufacturing

People	Deep and Focused Pipeline	Scalable Mammalian Manufacturing
 Dimension Therapeutics provided technology base Ultragenyx Gene Therapy has built in-house process discovery, definition, and development Internal knowledge de-risks scale up and tech transfer 	 2 clinical-stage programs OTC, GSDIa 1 partnered clinical program Hem A 1 late-stage research Wilson 4 early-stage research CDD, PKU, Citrullinemia type I, Undisclosed 	 HEK293 HeLa producer cell line Internally controlled process development Scalable up to 2,000L



Gene Therapy Pipeline: Deep and Focused


Candidate	Description	Pre-Clinical IND Phase 1 Phase 2 P	Phase 3 Est'd Patients in Dev. World
DTX301	AAV8-OTC Gene Transfer	Ornithine Transcarbamylase Deficiency	~10,000
DTX401	AAV8-G6Pase Gene Transfer	Glycogen Storage Disease Type Ia	~6,000
BAYER DTX201	AAV-FVIII Gene Transfer	Hemophilia A	~144,000
UX701	AAV-ATP7B Gene Transfer	Wilson Disease	>50,000
UX055	AAV9-CDKL5 Gene Transfer	CDKL5 Deficiency Disorder	~30,000
UX501	AAV8-PAH Gene Transfer	РКИ	~50,000
UX601	AAV8-ASS1 Gene Transfer	Citrullinemia type I	~2,000
UX067 (Partnered)	Undisclosed		>10,000

Combination Liver Metabolic Diseases (OTC, GSDIa, PAH, ASS1 +1, Wilson) and Neurology (CDKL5)



Ultragenyx Gene Therapy AAV Vector Production Vector Discovery to GMP Manufacturing

PD & manufacturing across 15 ml to 2,000L continuum – scaling factor > 130,000



Product yield consistency maintained across scale



DTX401 Program for Glycogen Storage Disease Type Ia (GSDIa)

Phase 1/2 study of adeno-associated virus serotype AAV8-G6Pase Gene Transfer

DTX401 AAV8 for GSDIa

- GSDIa: Autosomal recessive, inborn error of glucose metabolism; deficient glucose-6-phosphatase (G6Pase)
- Key symptoms/prognosis
 - Hypoglycemia leading to significant morbidity and mortality
 - Long-term liver and renal disease
 - Impaired growth and delayed puberty
 - Severe long-term complications (70-80% patients)
- Treatment limited; only curative approach is liver transplantation





• WW prevalence: 6,000

DTX401 Cohort 2 Update: Improvements In Glucose Control and Other Metabolic Parameters in all Patients

Ultragenyx Announces Positive Data from Phase 1/2 Study of DTX401 Gene Therapy in Glycogen Storage Disease Type Ia

Increased Time to Hypoglycemia and Reduction in Cornstarch Use in Cohorts 1 and 2; Improvement of Additional Key Metabolic Measures Observed

Cohort 1 Patients Continue to Demonstrate Long-Term, Durable Responses

Company to Enroll Three Patients in Expansion Cohort to Confirm 6.0 × 10^12 GC/kg Dose as Optimal Dose for Phase 3 Study

Novato, Calif., — **September 4, 2019** — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced positive data from the second dose cohort of the ongoing Phase 1/2 study of DTX401, an adeno-associated virus (AAV) based gene therapy for the treatment of glycogen storage disease type Ia (GSDIa). All three patients in Cohort 2 have shown a clinical response with improvements in glucose control and other metabolic parameters compared to baseline.

Moving to Extension Cohort to Confirm 6e12 GC/kg dose; Data Expected 1H 2020




DTX401 Phase 1/2 Study: Demographics

Cohort 2 patients generally heavier and received more than 3x GC total dose

	Cohort 1 (2e12 GC/kg)			Cohort 2 (6e12 GC/kg)		
	Pt 1	Pt 2	Pt 3	Pt 4	Pt 5	Pt 6
Study Site	UCONN	UMICH	UCONN	UT	UMICH	UCONN
Gender	Male	Female	Male	Male	Male	Male
Age (yrs)	28	57	51	31	19	39
Genotype	c.247C>T c.1039C>T	c.1039C>T (homozygous)	c.247C>T c.1039C>T	c.379_380dup (homozygous)	c.247C>T c.323C>T	c.79del c.189G>A
Weight (kg)	57	59	80	114	74	93
Total GC	1.14e14	1.19e14	1.60e14	6.00e14	4.47e14	5.58e14
Baseline Treatment	Cornstarch	Cornstarch + Continuous Feed	Cornstarch	Cornstarch	Cornstarch	Cornstarch
On Study (wks)	52	52	52	34	25	19



DTX401 Cohort 1 Long-term Data Demonstrates Improvement in Time to Hypoglycemia



Cohort 1, Patient 1

- 103% improvement in time to hypoglycemia
- 100% reduction in daily cornstarch (off cornstarch completely)


Cohort 1, Patient 2

- 159% improvement in time to hypoglycemia
- 56% reduction in daily cornstarch

Cohort 1, Patient 3

- 20% improvement in time to hypoglycemia
- 79% reduction in daily cornstarch (wk 52)

DTX401 Cohort 2 Data Demonstrates Improvement in Glucose Control



Cohort 2, Patient 4

- 15% improvement in time to hypoglycemia
- 69% reduction in daily cornstarch


Cohort 2, Patient 5


- 22% improvement in time to hypoglycemia
- 16% reduction in daily cornstarch

Cohort 2, Patient 6

- 58% improvement in time to hypoglycemia
- 68% reduction in daily cornstarch (Wk 18)

DTX 401 Cohort 2: Insulin Surges Drove Hypoglycemia





 20x insulin surges in Patients 5 & 6 during fasting challenge at Week 6, one hour after cornstarch consumption



DTX401: Clinically Significant Reduction of Daily Cornstarch Use Across Both Cohorts

	Cornstarch consumption (grams)						
	Cohort 1 (2e12 GC/kg)			Cohort 2 (6e12 GC/kg)			
Visit	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6	
Baseline	405	171	269	325	268	329	
W6	355	165	255	270	268	341	
W12	160	165	138	265	270	253	
W24	94	96	76	100 <i>(-69%)</i>	224 (-16%)	105 <i>(-68%)*</i>	
W52	0 (-100%)	76 (-56%)	57 (-79%)	NR	NR	NR	



*Cornstarch level at week 18

NR=Not yet reached

DTX401 Cohort 2: Meaningful Improvements in Other Metabolic Parameters

- Lower lactate levels after treatment compared to baseline and compared to Cohort 1
- Consistent early reductions in liver fat fraction (representative of glycogen storage) as measured by MRI across all Cohort 2 patients



DTX401: No Safety Issues Observed in Cohort 1 or 2

- Mild asymptomatic elevation in ALT levels in 4 patients
 - Successfully treated with a tapering course of steroids
- No infusion-related adverse events
- All adverse events have been Grade 1 or 2
- No treatment related SAEs






DTX301 Program for Ornithine Transcarbamylase (OTC) Deficiency

Phase 1/2 study of adeno-associated virus serotype AAV8 vector encoding human OTC

DTX301 AAV8 for OTC Deficiency AAV8 gene therapy for stable expression of OTC

- OTC Deficiency: X-linked urea cycle disorder, genetic defect in ammonia detoxification
- Key symptoms/prognosis: Acute hyperammonemic episodes that can lead to hospitalization, adverse cognitive & neurological effects, death
- Treatment limited; only curative approach is liver transplantation

• WW prevalence: ~10,000, 80% late-onset






DTX301: Two Patients Continue to Demonstrate Long-term Normalization of Ureagenesis

- Sustained normalization of ureagenesis at 52-78 weeks
- Clinically and metabolically stable, while discontinuing all alternate pathway medications
- Liberalized protein-restrictive diet without hyperammonemia concerns
- One patient had proven Influenza illness without hyperammonemia episode

Cohort 3 (1e13 GC/kg dose) update Q4 2019




Cohort 1, Patient 1 – Durable Normalization of Ureagenesis Liberalized diet and clinical stability off medications since ~Week 24



34

Cohort 2, Patient 4 – Durable Normalization of Ureagenesis Liberalized diet and clinical stability off medications since ~Week 24







UX701 for Wilson Disease

UX701 for Wilson Disease Next Gene Therapy program, entering the clinic in 2020

- Wilson Disease: Causes copper to accumulate in liver, brain and other vital organs
- Key symptoms/prognosis: Liver failure, neurological deterioration, death
- Standard of Care: Chelation therapy and dietary restriction
 - Many patients still experience liver/neurological deterioration
- WW prevalence: >50,000
- Initial preclinical studies completed
 - Novel version of ATP7B developed
 - Capsids from REGENXBIO
 - IND filing expected 2020






Untreated KO Mice

1x10¹¹ GC Treated Mice

Reduced liver copper accumulation leading to improved liver pathology in preclinical models



AAV Therapy Pumps Copper from the Liver into Blood and Bile

0

Golai

Bile canaliclus

Nucleus

0

Junction with

GI Tract

adjacent hepatocyte

Cu Excreted Into Bile &

With AAV Therapy

ATP7B* is formed and pumps copper from cytoplasm into the Golgi

Cp-Cu 👩

∠B

ATP7B*

0

Liver Cell with

AAV Therapy

ATOX1

Loads copper onto ceruloplasmin to secrete into the serum

→ CTR1

0

Excretes excess copper into the bile to exit the body

Sinusoidal blood

Free Copper Pumped into cell And to the Golai

AAV

Functionality normalized

ATP7B*

Wilson disease liver

Copper toxicity

treated

After AAV GT with ATP7B*

AAV ATP7B*



Truncated

ATP7B


Free Cu

Cu-Cp


Cu loaded onto Ceruloplasmin

ATP7B Deletion A – Key Therapeutic Properties


Rapid reduction in free liver copper, increased copper ceruloplasmin and reduced liver pathology



Reduction in Liver Pathology



Increase in Ceruloplasmin



Study Design

- Vector: DelA
- At T_0 mice = 6 8 weeks old
- Duration of study: 4 weeks





UX053 Program for Glycogen Storage Disease III

UX053 for Glycogen Storage Disease III Lead mRNA preclinical program, entering the clinic in 2020

Genetics

Autosomal recessive mutation in the AGL gene leading to glycogen accumulation in the liver and muscle


Clinical Presentation (based on literature)

- Beginning in infancy:
 - Hypoglycemia, hyperlipidemia, increased LFTs, hepatomegaly
- Later in Life
 - Fibrosis and cirrhosis
 - Cardiomyopathy, hypotonia, myopathy

Current Management

- High protein, cornstarch, fructose / galactose
- Hypoglycemia prevention
- Liver transplant


WW prevalence: ~10,000



IND-Enabling Studies Underway IND Filing Expected 2020



Dose-Response for AGL mRNA-LNP in GSDIII Mouse Model Reduction in liver glycogen, and an increase in blood glucose



X= dose undisclosed


Serum Glucose


Dose-response after a single dose of AGL-mRNA to reduce liver glycogen and stimulate increase in serum glucose (24 hours post-dose shown)



AGL mRNA-LNP Reduces Liver Glycogen in Single Dose Levels approach normal and are maintained for 48 hours in mouse model







Glycogen levels are reduced and hepatocyte hypertrophy is completely resolved after a single dose, and maintained for 48 hours. PD Response correlates with liver delivered protein levels.





UX068

Double-Trigger Prodrug for Creatine Transporter Deficiency

UX068 for Creatine Transporter Deficiency Lead small molecule preclinical program, entering the clinic in 2020

Genetics: X-linked recessive disorder due to mutations in SLC6A8

- Leading cause of X-linked intellectual disability in males
- Females can have mild to severe phenotype


Clinical Presentation (based on literature)

- Neurological deficits
 - Autism, speech/language developmental delays
 - Cognitive / developmental impairment
 - Motor skill delays, extrapyramidal symptoms
 - Seizures
 - Brain Cr levels range from undetectable to ~20 % of normal Non-CNS deficits
 - Muscle hypotonia and hypotrophy

Current Management: No SOC, only supportive care, AEDs effective for seizures

WW prevalence: >50,000

<u>Mechanism of Action</u>: Prodrug traverses the BBB and cell membrane and releases creatine to neurons




IND-Enabling Studies Underway IND Filing Expected 2020



UGX-developed Rat KO Model using CRISPR-technology

MR Spectroscopy, a clinically relevant biomarker, is used to characterize creatine in this animal model



MR Spectroscopy discriminates total brain creatine by genetic phenotype



Widespread Prodrug-derived Brain Creatine Distribution Creatine is delivered throughout the brain, including cortex and hippocampus

Imaging Mass-Spec for d3-Creatine (prodrug derived) Wild Type Rat CrT KO rat CrT KO rat **Endogenous creatine Prodrug derived d3-Creatine** Endogenous creatine Cortex **Hippocampus** Nissl staining **Hypothalamus** d3-Cr imaging Mass Spec

40 mg/kg dosed over 8 hours to SLC6A8 KO-rat, brains harvested after 24 hours





GTX-102 Program for Angelman Syndrome

Partnership to develop GeneTx's antisense oligonucleotide (ASO)

New Partnership to Advance GTX-102 for Angelman Syndrome

- Significant unmet need: ~60k patients WW, ~22k in U.S., serious disease with no approved treatment options
- Clear biology of disease: Disease mechanism well understood, ASO treatment validated and targets disease directly
- Promising preclinical work completed by GeneTx
 - IND expected 1H 2020
 - Orphan Drug Designation and Rare Pediatric Disease Designation Granted

Deal terms:

- \$20M upfront payment for exclusive option to acquire GeneTx
- Option begins after IND acceptance; Can be extended with \$25 million payment to earlier of 30 months from first patient dosing in Phase 1/2 study or 90 days after study results available
- During exclusive option period, GeneTx funds development; Ultragenyx provides strategic guidance, clinical expertise, staff support



Angelman Syndrome Debilitating disease with no treatment options

- Serious neurogenetic disorder
 - Estimated prevalence: 1 in 15,000
- Significant unmet need
 - Lack of speech
 - Cognitive impairment
 - Motor dysfunction
 - Seizures
 - Sleep disorder
- No currently approved therapies
 - Not neurodegenerative, potential for reversal of symptoms












GTX-102 ASO designed to activate the paternal gene

- Angelman defined by loss of expression of single gene UBE3A
 - Paternal UBE3A gene silenced in all mammals, but protein expressed by maternal allele
 - Angelman patients have deletion or mutation preventing maternal expression
- GTX-102 ASO reactivates the paternal UBE3A gene
 - Knocks down paternal UBE3A-antisense transcript (UBE3A-AS)
 - GTX-102 unique in targeting all implicated antisense regions




Preclinical Proof of Concept: Specific ASO Discovered with Potent Impact on Releasing Paternal Gene Expression

Human Neuronal Stem Cells

UBE3A-AS knockdown by nearly 100% in human AS neurons after treatment with GTX-102 in vitro. Direct correlation with UBE3A RNA supporting robust reactivation of the paternal UBE3A gene.






Non-Human Primates

Single-dose of GTX-102 in wild type monkeys demonstrates substantially increased paternal UBE3A gene expression in key brain region. Additional NHP data show broad brain distribution of antisense knockdown.

Relative Increase of Paternal UBE3A Expression in Motor Cortex after Single Dose of GTX-102



Dindot et al., manuscript in preparation



Finance and Business Summary

Financial Overview as of June 30, 2019



- Total Revenue (2Q19):
 \$24.1 million
- Total RARE Crysvita Revenue (2Q19): \$20.2 million
- Cash¹: \$618.3 million
- Cash Used in Operations (1H19): \$184.8 million
- No Debt



¹Cash, cash equivalents, and available-for-sale investments as of June 30, 2019

2019 Will Fuel Continued Value Expansion



- 2 commercially approved products in 3 major geographic regions
- 34 active or completed clinical studies
- 14+ programs in the development pipeline

- Continue successful global launches of Crysvita and Mepsevii
- UX007 NDA submitted
- DTX301 and DTX401 data readouts
- Begin building our AAV
 GMP manufacturing facility
- Prepare for up to 3 INDs to be filed in 2020
- Active on BD front

- Phase 3 gene therapy studies
- Launch UX007 for LC-FAOD if approved
- Initiate clinical trials for Wilson, GSDIII, and CTD programs
- Incorporate other BD deals into the pipeline






Appendix

Review of KHK Co-Promotion and Profit Share

	U.S. AND CANADA	EUROPE	LATIN AMERICA
Commercialization	 Ultragenyx launches KHK books sales 50/50 profit share for 5 years then tiered revenue share Shared commercial activities over time 	KHK commercializes and books sales	Ultragenyx commercializes and books sales
Royalties	After 5 years, tiered revenue share in mid to high 20% range to Ultragenyx after profit share period	Up to 10% royalty to Ultragenyx	Low single-digit royalty to KHK
Commercial supply	KHK supplies; price is double-digit percentage of net sales	NA	KHK supplies; price is double- digit percentage of net sales



Revenue to Ultragenyx Maintained After Transition from Profit Share to Royalty in U.S.



Key Licenses & Intellectual Property

Product	License	Intellectual Property/Royalties
Burosumab (XLH, TIO)	КНК	 Shared rights to U.S. patents to generic and specific antibodies and use for treatment of XLH (2022-2032)¹ See summary of collaboration
Vestronidase Alfa (MPS 7)	St. Louis University	Composition and use for treatment of MPS 7 (2035)Low single-digit royalty
UX007 (LC-FAOD)	Baylor Research Institute (BRI)	 Composition (2020-2029/30)¹ Use for treatment of LC-FAOD (2020) Mid single-digit royalty
DTX301 (OTC Deficiency)	Sub-License from REGENXBIO of UPENN IP	 Composition and use for treatment of OTC Deficiency (2022-2035) Low to mid single-digit royalty
DTX401 (GSDIa)	Sub-License from REGENXBIO of UPENN IP	Composition for treatment of GSDIa (2022-2024)Low to mid single-digit royalty
	NIH (Non-Exclusive)	Composition for treatment of GSDIa (2034)Low single-digit royalty

ultrageny

¹Includes projected U.S. patent term extension

Crysvita[®] Exclusivity Summary






CRYSVITA

Mepsevii[™] Exclusivity Summary

Mepsevii (vestronidase alfa-vjbk)





UX007 Exclusivity Summary

